Pharmaceutical composition and food composition for enhancing erythropoietin gene expression
5-acetyl-1-benzylpyrrolidin-2-one compositions enhance EPO gene expression, addressing the lack of evidence in existing literature, and promote EPO production for improved anemia treatment and endurance.
Patent Information
- Application Number
- JP2023078220
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-10
- Publication Date
- 2024-11-21
- Estimated Expiration
- 2043-05-10
AI Technical Summary
Existing literature lacks evidence of 5-acetyl-1-benzylpyrrolidin-2-one's ability to enhance erythropoietin (EPO) gene expression, which is crucial for promoting red blood cell production.
The compound 5-acetyl-1-benzylpyrrolidin-2-one is identified to enhance EPO gene expression, thereby promoting EPO production.
The pharmaceutical and food compositions containing 5-acetyl-1-benzylpyrrolidin-2-one increase EPO production, improving anemia, endurance, and reducing fatigue by enhancing EPO gene expression.
Smart Images

Figure 2024162576000001
Abstract
Description
[Technical field]
[0001] The present invention relates to a pharmaceutical composition and a food composition for enhancing expression of an erythropoietin (EPO) (hereinafter simply referred to as "EPO") gene. [Background technology]
[0002] 5-Acetyl-1-benzylpyrrolidin-2-one, the active ingredient of the pharmaceutical composition and food composition of the present invention, is a compound in which an acetyl group is attached to the carbon at the 5-position of pyrrolidine, a benzyl group is attached to the nitrogen at the 1-position, and an oxygen double bond is attached to the carbon at the 2-position.
[0003] This 5-acetyl-1-benzylpyrrolidin-2-one is suggested as an example of a synthetic compound in the following Non-Patent Document 1, but its existence is merely suggested, and no specific attributes are disclosed or suggested.
[0004] Furthermore, as shown in the following Patent Documents 1 to 5, the present inventors have already discovered that 5-acetyl-1-benzylpyrrolidin-2-one has PDE5 inhibitory effects, estradiol production promoting effects, muscle hypertrophy promoting effects, xanthine oxidase inhibitory effects, and 5-aminolevulinic acid production promoting effects, but have not discovered its effect of enhancing EPO gene expression.
[0005] As shown in Non-Patent Document 2 below, it is known that the promotion of production of EPO, a hematopoietic hormone that promotes the production of red blood cells, is caused by the EPO gene. That is, the EPO gene is a gene that codes for EPO, and an increase in the amount of EPO has been confirmed in mice in which the EPO gene is overexpressed, and it is known that EPO production is caused by the enhanced expression of the EPO gene. [Prior art documents] [Non-patent literature]
[0006] [Non-Patent Document 1] DESKUS, et al., "SYNTHESIS OF 5S-(1-OXOALKYL AND ARYL)-2-PYRROLIDINONE DERIVATIVES", SYNTHETIC COMMUNICATIONS, USA, Marcel Dekker, Inc., May 1998, Vol. 28, No. 9, pp. 1649-1659 [Non-Patent Document 2] Robert A. Jacobs and 9 others, "Erythropoietin promotes hippocampal mitochondrial function and enhances cognition in mice", Communications Biology 4, UK, Nature Portfolio, 2021, Article number: 938 [Patent documents]
[0007] [Patent Document 1] Patent No. 6537689 [Patent Document 2] Patent No. 6578046 [Patent Document 3] Patent No. 6962630 [Patent Document 4] Patent No. 7134541 [Patent Document 5] Patent No. 7253301 Summary of the Invention [Problem to be solved by the invention]
[0008] As mentioned above, there is no literature that discloses or suggests that 5-acetyl-1-benzylpyrrolidin-2-one has the effect of enhancing the expression of the EPO gene. [Means for solving the problem]
[0009] As a result of intensive research, the present inventors discovered that 5-acetyl-1-benzylpyrrolidin-2-one has the effect of enhancing the expression of the EPO gene, and thus has the effect of promoting EPO production, thereby completing the present invention.
[0010] Specifically, the present invention relates to a pharmaceutical composition or a food composition for enhancing EPO gene expression, which comprises 5-acetyl-1-benzylpyrrolidin-2-one as an active ingredient. Effect of the Invention
[0011] The pharmaceutical composition and food composition for enhancing EPO gene expression of the present invention promote EPO production by enhancing the expression of the EPO gene, and are expected to have effects such as promoting red blood cell production, improving anemia, improving endurance, and reducing fatigue. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] The present invention relates to a pharmaceutical composition for enhancing EPO gene expression, which contains 5-acetyl-1-benzylpyrrolidin-2-one as an active ingredient. The pharmaceutical composition of the present invention enhances the expression of the EPO gene, thereby promoting EPO production and contributing to the prevention and / or treatment of renal anemia.
[0013] 5-acetyl-1-benzylpyrrolidin-2-one is a compound in which an acetyl group is attached to the carbon at the 5th position of pyrrolidine, a benzyl group is attached to the nitrogen at the 1st position, and an oxygen double bond is attached to the carbon at the 2nd position. The structural formula is shown in Chemical formula 1 below. The molecular formula is C 13 H 15 NO 2 It is.
[0014] [ka]
[0015] EPO is known to contribute to hematopoiesis by increasing red blood cells.
[0016] The pharmaceutical composition of the present invention promotes the production of EPO by enhancing the expression of the EPO gene, which is a gene that encodes EPO, and thereby contributes to the prevention and / or treatment of renal anemia.
[0017] The pharmaceutical composition according to the present invention can be used as a drug or quasi-drug and can be in various forms. These drugs or quasi-drugs can be in dosage forms suitable for oral administration, such as powders, pills, tablets (e.g., coated tablets, sugar-coated tablets, chewable tablets, etc.), capsules (e.g., hard or soft gelatin capsules, etc.), granules, and oral liquids (e.g., emulsions, suspensions, syrups, etc.).
[0018] In addition, the compound may be in a dosage form suitable for rectal administration such as a suppository; a dosage form suitable for intravascular administration such as an injection or infusion, intramuscular administration, subcutaneous administration or intradermal administration such as an ointment, cream, gel, or liquid (including eye drops, eyewash, etc.); i.e., a dosage form suitable for parenteral administration, but oral administration is preferred.
[0019] When the pharmaceutical composition of the present invention is used in the form of tablets, granules, capsules, or chewable tablets, known carriers such as tableting aids, granule processing aids, capsule processing aids, etc. can be used.
[0020] Examples of tableting aids include granulated sugar, white sugar, powdered sugar, reduced maltose syrup powder, lactose, glucose, pullulan, erythritol, starch, dextrin, and other sugars, crystalline cellulose, gum arabic, soybean curd, and other dietary fibers, corn protein, calcium phosphate, and other food calcium, food extracts, dried food powders, natural fruit juice powders, surfactants such as sucrose fatty acid esters, powdered oils and fats, glycerin, fatty acid esters, and other oils and fats, and various sweeteners, various acidulants, and various flavors used in chewable tablets, and shellac, corn protein, yeast cell walls, starch, reduced maltose syrup, sugarless sugar coating, maltitol, glycerin, sorbitol, HPMC, HPC, and the like, as coating materials. However, there are no particular limitations as long as the effects of the present invention are not impaired.
[0021] Furthermore, there are no particular limitations on the granule processing aid as long as it does not impair the effects of the present invention, and examples include all sugars such as granulated sugar, white sugar, powdered sugar, reduced maltose syrup powder, lactose, glucose, pullulan, erythritol, starch, dextrin, and the like, dietary fibers such as crystalline cellulose and gum arabic, corn protein, food calcium such as calcium phosphate, food extracts, dried food powders, natural fruit juice powders, and the like.
[0022] Furthermore, there are no particular limitations on the capsule processing aids as long as they do not impair the effects of the present invention. Examples of such aids include all sugars, such as granulated sugar, white sugar, powdered sugar, reduced maltose syrup powder, lactose, glucose, pullulan, erythritol, starch, dextrin, and other sugars, dietary fibers, such as crystalline cellulose and gum arabic, corn protein, food calcium, such as calcium phosphate, food extracts, dried food powders, and natural fruit juice powders, for preparing hard capsules, and content viscosity adjusters, such as edible oils and fats, beeswax, and glycerin fatty acid esters, for preparing soft capsules.
[0023] Tablets can usually be prepared using a tablet press, but they can also be made into chewable tablets by blending flavoring materials into the tablets, or the tablet surface can be coated using an automatic coating machine, a spray granulator, or a hand pan. Granules can be formed using various granulators, such as spray granulator type, kneading (extrusion) type, or high-speed agitator granulator type. Capsules can be prepared using capsule filling machines (hard and soft types) by mixing capsule assistants.
[0024] The present invention also relates to a food composition for enhancing EPO gene expression, comprising 5-acetyl-1-benzylpyrrolidin-2-one as an active ingredient. The food composition of the present invention is expected to promote EPO production by enhancing EPO gene expression, and thus promote red blood cell production, improve anemia, improve stamina, and reduce fatigue.
[0025] The food composition for enhancing EPO gene expression of the present invention can be used as a food, beverage, or animal feed, for example, as a health food, functional food, food for specified health uses, beauty food, or nutritional supplement. These foods, beverages, and animal feeds may be in the form of known foods such as ice cream, jelly, candy, chocolate, and chewing gum, or drinking water such as tea and juice. They may also be in the form of liquids, powders, granules, capsules, tablets, etc.
[0026] The intake amount of the pharmaceutical composition for enhancing EPO gene expression and the food composition for enhancing EPO gene expression according to the present invention is not particularly limited, and can be appropriately selected depending on the age, weight, symptoms, etc. of the user or patient or animal that takes the composition, as well as the dosage form. The intake period can be determined arbitrarily depending on the age and symptoms of the user or animal that takes the composition. EXAMPLES
[0027] Next, the present invention will be described in more detail with reference to examples. However, the present invention is not limited to the following examples as long as it does not depart from the gist of the present invention.
[0028] Measurement of EPO gene expression using DNA microarray In this study, human liver-derived cells Hep G2 were cultured in the presence of 5-acetyl-1-benzylpyrrolidin-2-one, and DNA microarray analysis was performed to confirm whether EPO gene expression was enhanced. EPO is known to be produced in the human body not only in the kidneys but also in the liver.
[0029] Liver-derived cells Human hepatoma cell line Hep G2 Obtained from the National Institutes of Biomedical Innovation, Health and Nutrition.
[0030] Sample Preparation 1) 100 μL of DMSO was added to 10 mg of 5-acetyl-1-benzylpyrrolidin-2-one to dissolve it, and the test substance was serially diluted with DMSO to a concentration of 50 mM. 2) The test substance was further diluted with cell culture medium to a concentration of 50 μM.
[0031] <method> Preparation of Hep G2 cells 1) 2 x 10 Hep G2 cells 5 5 mL of cells were seeded onto a 6 cm dish at a cell concentration of 100 cells / mL. 2) 24 hours after seeding, adhesion was confirmed, the cell culture medium was removed, and 5 mL of fresh cell culture medium containing the test substance (final concentration 50 μM) was added to each well. 3) After addition, the cells were cultured for 24 hours, the cell culture medium was removed, and the adherent cells were washed with PBS. The obtained cells were then used for RNA extraction and DNA microarray analysis as described below.
[0032] RNA Extraction 1) RNA was extracted from the cells obtained by the above cell preparation using RNAiso plus and purified using the RNeasy MinElute Cleanup Kit.
[0033] DNA microarray analysis 1) cDNA was synthesized from the RNA sample using the Low Input Quick Amp Labeling Kit (Agilent), and Cy3-labeled cRNA was synthesized and purified. 2) Using the Gene Expression Hybridization Kit (Agilent), each labeled cRNA was fragmented and applied to a Whole Human Genome Microarray Ver2.0 (Agilent), followed by hybridization at 65°C for 17 hours. 3) The array slide was washed using Gene Expression Wash Buffer 1 and 2 (Agilent). 4) Array images scanned with a microarray scanner (GenePix 4000B, Molecular Devices) were digitized using array analysis software GenePix Pro (Molecular Devices). Fluorescence intensity values were normalized, and the ratio of the test substance group to the control was calculated.
[0034] <result> In human liver-derived cell line (HepG2), EPO gene expression was increased 1.96-fold in the presence of 5-acetyl-1-benzylpyrrolidin-2-one, suggesting that 5-acetyl-1-benzylpyrrolidin-2-one increases EPO gene expression and thus promotes EPO production.
Claims
1. A pharmaceutical composition for enhancing erythropoietin gene expression, comprising 5-acetyl-1-benzylpyrrolidin-2-one as an active ingredient.
2. A food composition for enhancing erythropoietin gene expression, comprising 5-acetyl-1-benzylpyrrolidin-2-one as an active ingredient.
Citation Information
Patent Citations
Pharmaceutical composition and food composition for promoting estradiol production
JP6537689B1
Pharmaceutical composition for inhibiting PDE5 and food composition for inhibiting PDE5
JP6578046B1
Pharmaceutical composition and food composition for promoting muscle hypertrophy
JP6962630B1
Pharmaceutical composition and food composition for inhibiting xanthine oxidase
JP7134541B1
Pharmaceutical composition and food composition for promoting 5-aminolevulinic acid production
JP7253301B1
